The AI-HOPE-TGF-Beta platform rapidly identified a significant survival disadvantage among EO H/L CRC patients treated with FOLFOX who harbored TGF-β pathway alterations, a finding subsequently validated by Kaplan–Meier analysis (p = 0.029) and consistent with the survival patterns reported in our primary analyses. The gene discussed is TGFB1; the disease is colorectal carcinoma.